



20
19

Annual
report

**Another year
of research
and
dissemination
to overcome
Alzheimer's**

pasqual
maragall
foundation

barcelonaβeta
BRAIN RESEARCH CENTER

20
19

**A year
of intense
activity**

Edition **Pasqual Maragall Foundation**
Barcelonabeta Brain Research Center Foundation

Wellington, 30
08005 Barcelona
933 160 990

info@fpmaragall.org
info@barcelonabeta.org
www.fpmaragall.org
www.barcelonabeta.org

Art direction **marcmontala.com**

Publication date July 2020

Total or partial reproduction of this publication, treatment in any form or by any means, electronic, mechanical, photocopying, recording, or other methods, or its loan, rent or any other form of cession of use of the copy is not allowed without prior written permission of the copyright holder.

2019

Annual report



Greeting	06
Determination	08
Alzheimer's disease today	09
2019: let's move forward together	10
The year in numbers	12
Credibility	14
Figures	15
Alfa Study	16
Alzheimer's Prevention Program	17
Research projects	20
International collaborations	25
Clinical trials	27
Scientific publications	28
Dissemination of results	30
Competitive grants	31
Congresses	34
Transformation	36
Therapeutic groups	37
Dissemination activities	38
Connection	48
Network of partners and donors	49
Actions and solidarity entities	50
Solidarity celebrations	53
Challenges and solidarity sports	54
Solidarity schools	55
Trust	56
About us	57
Origin and destination of resources	58
Collaborators	60
Academic collaborators	61
Board	62

Greeting



This greeting is very special to me. This is my last one as director because last February, I left the post, after twelve years of being fully involved in this great initiative. I am leaving the responsibilities of management once the strategic plan has been drawn up for the coming years, a new stage in which I will support and remain closely linked to the Foundation as Vice-President of the Board. I hand over the management of the Pasqual Maragall Foundation to Dr. Arcadi Navarro, who takes on the challenge with the same goals and the same determination to end Alzheimer's disease. The Foundation is in very good hands, and I thank Dr. Navarro his willingness and commitment.

In this process of transition, we did not expect that, last February, our president, Diana Garrigosa, would leave us in a totally unexpected way. It is still difficult for us to assume it. And we will miss her a lot, for her personal value, for her determination and for the impetus she constantly exerted to develop the entity. The memory of Diana Garrigosa will always remain with us.

I am writing these words while facing a new personal and vital stage and at a very complex time, also unexpected, due to the coronavirus pandemic that has so profoundly impacted our lives, especially those of groups considered at risk, such as this is the case for people with Alzheimer's and their caregivers.

So without losing sight of everything that is happening, we need to take stock of the year 2019, which is reflected in the report you have in your hands.

2019 has been a year of growth and consolidation of many of our projects. The ALFA study dedicated to Alzheimer's prevention has continued to consolidate more strongly than ever, thanks to the sustained support of the "La Caixa" Foundation. In our Clinical Research Unit, this year 2019 more than 2,000 visits have been made to the people participating in the study, more than 20,000 biological samples have been collected and nearly 1,000 MRIs have been acquired, in the frame-work of 14 different scientific studies.

These scientific studies include the continuation of the European EPAD project for the prevention of dementia as well as the AMYPAD, an international project aimed at improving knowledge and diagnosis of the disease with neuroimaging techniques. At the local level, we highlight the launch of the PENSA study, together with the Hospital del Mar Institute for Medical Research, a non-pharmacological clinical trial also aimed at the prevention of dementia.



“I’ve been lucky enough to lead this organization since its beginning and help it grow to where it is today.”

Our scientific activity is reflected in the year-on-year growth of our publications. Also in some recognitions, such as the National Prize for Scientific Patronage awarded at the end of last year by the Catalan Foundation for Research and Innovation for our work in promoting Alzheimer’s research. It was the last public event with our president, an award given to us personally by the President of the Generalitat.

On the social side, we have continued to work to give visibility to those affected and their caregivers and to accompany them in their daily lives, through our program of therapeutic groups and numerous dissemination and awareness activities. Let’s highlight, in this sense, the campaign on the street “When you take care of yourself, Alzheimer’s takes a step back” that allowed us to remain aware of the importance of controlling risk factors for the prevention of the disease.

This is just a small summary of what you will find in the pages of this report where you can see the extensive and intense activity carried out. We will continue to work with the essential support of our Trustees, the more than 33,000 members who support us with their contributions, the entities of our Sponsorship Board and the collaborators and volunteers who help us whenever we need them.

I’ve been lucky enough to lead this organization since its beginning and help it grow to where it is today. It has been an extraordinary adventure from which I also take experiences and enriching learnings. In these farewell moments, I would like to express my gratitude for the commitment, effort and good work of all the extraordinary professionals, and of the first-level scientific team of the Pasqual Maragall Foundation and the Barcelonaβeta Brain Research Center. Do not doubt that we will make real the commitment expressed by Pasqual Maragall on the day he announced that he was suffering from the disease: “Nowhere is it written that Alzheimer’s is invincible.” Every day we are closer.

Thank you for all these years and for continuing by our side.

Jordi Camí
Director

Barcelona, June 2020



deter mina tion.

**"Nowhere is it written
that Alzheimer's is invincible."**

Pasqual Maragall said this and we will not tire of working to achieve
a world without Alzheimer's or neurodegenerative diseases.

01.

1.01

Alzheimer's disease today

Every day thousands of new cases of dementia are diagnosed in the world, whose main cause is Alzheimer's. It is estimated that in the world there are about **50 million cases of dementia¹** and only in Spain, about **800,000 cases²**.



50 Million
cases



800,000
cases

≡

If we were able to delay only five years the start of the Alzheimer's, the number of sick people could be reduced to almost half³.

Every 3 seconds a new case of dementia is diagnosed in the world.



1 of every 10 people over 65 years old has Alzheimer's.



The **Pasqual Maragall Foundation** and the **Barcelonaβeta Brain Research Center** work tirelessly to find a solution. We are convinced that research is the only way out. And prevention is the key to stop the advance of the epidemic.



One of every three cases of dementia could be prevented making a change of life habits⁴.

1. Data from the World Health Organization (WHO). 2. Data from the World Alzheimer Report. 3. Data from the Alzheimer's Association Treatment Report: Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars. 4. Norton et al. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. *Lancet Neurol.* 2014 Aug(13);8:788-94

1.02

2019: let's move forward together




January

We identify cognitive and brain changes in people with subjective cognitive decline.



March

We begin the visits of two studies of the European project AMYPAD.



April

We determine **new cut-off values** that can expand the number of candidates for Alzheimer's prevention strategies.



June

We celebrate the **IV Annual Meeting of Partners and Participants**.



January

Solidarity concert by **Andrea Motis** and **Joan Chamorro**.



March

We promote the second edition of the **Brain Film Fest**, the international film festival about the brain.



March

Closing of the **"Cent by cent, let's remember"** campaign.



April

We launch the **#Alzheimer28A** campaign to ask political parties for a commitment for Alzheimer's.





1.03

The year in numbers

Aggregate data from the Pasqual Maragall Foundation and the Barcelonaβeta Brain Research Center.

Both entities are subject to an external annual audit.

Budget



Budget

€ **10,961.050**

Pasqual Maragall Foundation

€ **6,005,549**

BBRC Research Center

€ **4,955,501**



54.7 % FPM

45.3 % BBRC

Staff



31 %

42 Men



69 %

93 Women

Pasqual
Maragall
Foundation



29 %

25 Men



71 %

61 Women

BBRC
Research
Center



35 %

17 Men



65 %

32 Women

2019

Dissemination



1,120

Media appearances



48.303



6.908



3.027



771

+ 59,000

Followers on social networks



+ 800,000

Visualizations of the Blog "Let's speak about Alzheimer's"

Therapeutic Groups in Barcelona, Girona, Alcalá de Henares, Sevilla, Tenerife and Vigo.



170
Caregivers



Interventions in patient support groups in Galicia, Tenerife, Madrid and Andalusia.

Research



+ 2,000

Visits to participants



+ 21,000

Processed samples



+ 1,000

Magnetic Resonance Imaging (MRI) acquisitions

Social support



33,657

Members at the end of the year



+ 2,000

Donations



205

Solidarity actions



cre
dibi
lity.

**Scientific rigor and expert
knowledge in everything we do.**

At the Barcelonaβeta Brain Research Center, our research center, we carry out research on Alzheimer's prevention. The expertise of our multidisciplinary team ensures scientific rigor to advance knowledge to overcome the disease.

02.

2.01

Figures



+ 21,000

Processed
samples



+ 2,000

Visits to
participants*



+ 1,000

MRI
acquisitions



14

Study
protocols



+ 1,400

Clinical
sessions



+ 1,000

Cognition
sessions



+ 900

Nursing
sessions



- **42.4 %**
Clinical sessions
- **30.3 %**
Cognition sessions
- **27.2 %**
Nursing sessions

*In the same visit the participants can carry out different sessions.

2.02

Alfa Study



It is one of the research platforms dedicated to the early detection and prevention of Alzheimer's with a greater number of participants existing in the world.

The **Alfa Study** was launched in 2013 thanks to the support of the "la Caixa" Foundation, and is one of the research platforms dedicated to the early detection and prevention of Alzheimer's with a greater number of participants existing in the world.

It is made up of **2,743 participants without cognitive impairment**, aged between 45 and 75, most of whom are sons and daughters of people with Alzheimer's.

Its goal is to gather information to **identify biomarkers and risk factors** to understand the natural history of Alzheimer's disease and to **design prevention strategies**.

2,743
Participants

On the first visit to the Alfa Study, participants underwent a series of tests (cognition tests, medical history, life habits, and some of them a MRI). Then, depending on the characteristics and availability of each person, participants are invited to participate in research projects that also include other additional tests, such as positron emission tomography (PET), lumbar puncture, or olfactory test, among others.

Thanks to these tests, which are carried out on a regular basis, researchers at our research center **have already published relevant advances in prestigious scientific journals**.

The Alfa Study
has the support of:

 **"la Caixa" Foundation**



2.03

Alzheimer's Prevention Program



The Alzheimer's Prevention Program is led by Dr. José Luis Molinuevo and is structured in two groups.

The BBRC's Alzheimer's Prevention Program is dedicated to the study of the preclinical and prodromal phase of Alzheimer's disease.

The **preclinical phase** includes a period characterized by changes in the brain that may begin decades before the onset of clinical symptoms.

The current research framework defines disease by criteria based on the presence of biomarkers associated with the pathology, such as the abnormal concentration of proteins in cerebrospinal fluid or its brain deposition detected by PET.

The Alzheimer's Prevention Program **is led by Dr. José Luis Molinuevo** and is structured in two groups that collaborate closely from a clinical, cognitive, genetic and biological and neuroimaging markers perspective.

1

Clinical Research Group, Biomarkers and Risk Factors



The **Clinical Research Group, Biomarkers and Risk Factors** is responsible for examining the **biological processes that precede the onset of dementia**, with the aim of establishing prevention programs for people who have no symptoms but are at risk of developing the disease.

The group is made up of experts in the field of genetics, clinical practice, biomarkers and neuropsychological assessment, and is led by Dr. **José Luis Molinuevo**.



► Members of the Clinical Research, Biomarkers and Risk Factors group

2.03



The aim of the group is establishing prevention programs for people who have no symptoms but are at risk of developing the disease.

Research lines



- Association between subjective cognitive decline and brain changes and objective cognitive performance.
- Association between sleep disorders, cognitive impairment and Alzheimer's disease.
- Role of pro-rejuvenating and pro-aging blood risk factors in Alzheimer's disease.
- Personalized study of the risk of developing dementia in order to offer personalized prevention plans.
- Role of vascular risk factors in the pathophysiology of Alzheimer's.
- Epidemiological studies on the role of pollution, anxiety, depression and other factors in Alzheimer's.
- Effect of dietary intake of omega 3 fatty acids on the preclinical phase of Alzheimer's.
- Multimodal interventions for the prevention of cognitive impairment.
- Study of reserve, resilience, and lifestyle to understand the brain mechanisms and risk factors that make some people resilient to disease.



2.03

2

Neuroimaging



The aim of the group is to reveal brain characteristics that can be suggestive of novel prevention strategies.



The **Neuroimaging Research Group** focuses on the study of MRI and PET images to reveal brain characteristics related to healthy aging and AD risk factors that can be suggestive of novel prevention strategies.

The group consists of experts in the acquisition, processing and analysis of complex neuroimaging data and led by Dr. **Juan Domingo Gispert**.

Research lines



- Brain correlations of the preclinical phase of Alzheimer's and disease risk factors.
- Improving the use of amyloid positron emission tomography imaging in clinical and research settings.
- Genetic determinants of brain phenotypes.
- New techniques for detecting the preclinical phase of Alzheimer's disease.
- Generation of an image repository of the preclinical phase of Alzheimer's disease.

► Members of the Neuroimaging Research Group



2.04

Research projects



PENSA Study is led by the BBRC and the Hospital del Mar Institute for Medical Research (IMIM)

1

PENSA Study



The PENSA Study is a new clinical trial that will study whether it is possible to slow down the cognitive impairment in stages prior to dementia.


The project is led by the BBRC and the Hospital del Mar Institute for Medical Research (IMIM), under the direction of Dr. José Luis Molinuevo (co-principal investigator of the study) and Rafael de la Torre (principal investigator of the study). It was launched in December 2019, has a duration of 17 months and will feature the participation of **200 people between 60 and 80 years** who are experiencing a decrease in memory or other cognitive abilities such as attention, ability planning or guidance, among others.

Its purpose is to investigate the effect on the progression of cognitive impairment of an intervention based on the monitoring of a healthy lifestyle, supplemented with a natural green tea compound called epigallocatechin gallate (EGCG).

This intervention consists of a **personalized action plan** based on your lifestyle and health indicators. Gradually, the participants will be helped to make appropriate changes to try to reduce the risk of cognitive impairment.

The PENSA Study is part of the international consortium **World Wide FINGERS**, an initiative dedicated to promoting projects for the primary prevention of cognitive impairment and dementia. **The project is funded with \$ 1 million by the Alzheimer's Association of the United States.**

Recruitment of candidates for the clinical trial will be extended through 2020 via an online form on the following website:
www.pensaalzheimer.org.



2.04



The aim of the study is to develop a method for the early diagnosis of Alzheimer's disease through a blood test.



Alzheimer's
Drug Discovery
Foundation

2

New study to diagnose the early stages of Alzheimer's with a blood test



In late 2019, the **Alzheimer's Drug Discovery Foundation**, an American philanthropic organization that has received funding from millionaires such as Bill Gates, Jeff Bezos and Leonard A. Lauder, awarded 2.8 million euros for a European project led by the University of Gothenburg, in which the BBRC participates. The aim of the study is to **develop a method for the early diagnosis of Alzheimer's disease through a blood test.**

"The development of a non-invasive diagnostic test will allow us, on the one hand, to identify people at risk of developing symptoms of the disease, and on the other, to facilitate the design of drugs, as we will improve and facilitate the selection of potential candidates to participate in prevention clinical trials", explains Dr. Molinuevo.

Researchers from Lund University in Sweden are also involved in the study, with the collaboration of Roche Diagnostics International Ltd.

3

Barcelonaβeta Dementia Prevention Research Clinic



The **Barcelonaβeta Dementia Prevention Research Clinic** is a project that **studies the risk, and its biological basis, of developing dementia five years from now.** The study offers to the participants a personalized action plan to try to reduce their risk.

During 2019, visits to study participants continued. Of these, 13 have already completed the program, which has consisted of a follow-up of approximately one year.

The study included a total of **300 participants between the ages of 60 and 80** who were experiencing a decrease in their cognitive abilities.

300
Participants

2.04



Most participants in the Alfa+ Study are also invited to undergo two PET sessions.

4

Alfa+



Alfa+ is a **cohort, prospective, and observational study** for the early identification of biomarkers associated with the preclinical phase, prior to the development of Alzheimer's disease.

The project involves **450 people** without cognitive impairment who perform different tests every three years, such as cognitive tests, extraction of cerebrospinal fluid by lumbar puncture, performing nursing tests and two MRIs.

450
Participants

5

PET



Most participants in the Alfa+ Study are also invited to undergo two positron emission tomography (**PET**) sessions, which take place at the Hospital Clínic facilities. The goal is to analyze these images to improve the detection of the preclinical phase of Alzheimer's.

In this study **PET tests of 18F-flute-metamol** are performed, which show the amount and location of beta amyloid, and **18F-FDG**, to analyze the greater or lesser activity of different brain areas.



2.04

6

Bio Alfa



The BioAlfa project has been funded by the European Union's Horizon 2020 research and innovation program.



The **BioAlfa** project aims to investigate whether certain blood factors that have been associated with aging or brain rejuvenation in mice can become potential therapeutic targets to combat Alzheimer's disease and other dementias in humans.

Since its launch in 2018, researchers have studied these factors in blood samples in participants of extreme ages, and in the next phase they will measure them in participants in the Alfa+ cohort.

The research is led by **Dr. Marc Suárez-Calvet**, under the direction of Drs. José Luis Molinuevo (Barcelona beta Brain Research Center) and E Blennow (Sahlgrenska Academy, University of Gothenburg).

The BioAlfa project has been funded by the Marie Skłodowska-Curie grant number 752310, within the framework of the **European Union's Horizon 2020** research and innovation program.

The project has also had the collaboration of the Blood and Tissue Bank, the Walnuts Study of the Barcelona Institute of Global Health, and the "la Caixa" Foundation, which supports the Alfa+ Study.



2.04



The aim is to improve knowledge of the molecular basis of Alzheimer's disease and to identify new biomarkers and risk factors.

7

Alfa Genetics



Alfa Genetics is a transversal study, which was launched to expand the cognitive, genetic, and brain characterization of Alfa Study participants.

The aim is to **improve knowledge of the molecular basis of Alzheimer's disease and to identify new biomarkers and risk factors** to be able to detect the disease early.

8

Alfa Cognition



Alfa Cognition is an observational and prospective study that **analyzes the relationship between the subjective perception of cognitive decline** and the presence, evolution, or risk of clinically objective cognitive impairment.

It also looks at the relationship between these parameters and the brain changes associated with Alzheimer's disease.

The study involves **200 people**, who perform neurological, neuroimaging, cognitive and lifestyle tests, and a blood draw.



1,700
Participants



During 2019, visits to participants continued until a total of about **1,700 people** at the closure of the study, at the second half of the year.

Tests include an MRI, an odor identification test, a blood sample, and an update on medical history and cognitive tests. The aim is to identify brain patterns associated with genetic variants related to the risk of developing Alzheimer's.

200
Participants

2.05

International collaborations



EPAD closed 2019 with more than 2,000 participants recruited from 29 centers in Europe.

1

EPAD



The **European Prevention of Alzheimer's Dementia Consortium (EPAD)** is a collaborative research project made up of 39 European institutions, including the BBRC.

39
European
institutions

Its goal is to **expand knowledge about the preclinical phase of Alzheimer's** and to develop a research infrastructure that will accelerate the decision-making in the development of candidate drugs to prevent the disease

The project was set up in 2015 and will end in June 2020, thanks to a six-month extension over the period initially set.

EPAD closed 2019 with more than **2,000 participants recruited from 29 centers in Europe**. The BBRC was one of the centers with the most active participants with a total of 253. Throughout the year, participants underwent regular checkups, cognitive, genetic, MRI and blood, saliva, urine, and cerebrospinal fluid extractions.

EPAD is funded by grant number 115736 from the Innovative Medicines Initiative, which is a joint initiative of the **European Commission's Horizon 2020** research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).



2.05



AMYPAD recruited more than 1,000 research participants throughout Europe in 2019.



2

AMYPAD



Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) is a European collaboration aimed at **improving the knowledge, diagnosis and treatment of Alzheimer's disease through the use of positron emission tomography (PET) cerebral amyloid.**

The project consists of 17 European institutions, including the BBRC.

The project consists of different parts: a **diagnostic study** to determine the value of amyloid PET as a diagnostic and therapeutic marker, a **prognostic study** to better understand the natural history of the disease, and a **proof-of-concept study** where models of disease evolution will be built.

In 2019, **the recruitment of participants began, with a total of more than 1,000.** Visits include a PET at the Hospital Clínic facilities. The BBRC leads the Prognostic study.

AMYPAD is funded by grant number 115952 from program 2 of the Innovative Medicines Initiative, which is a joint initiative of the **European Commission's Horizon 2020** research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

3

TRIBEKA



TRIBEKA is an initiative of the BBRC and the University of Edinburgh that aims to **identify brain disorders** prior to the onset of symptoms of Alzheimer's disease and other neurodegenerative diseases.

The consortium's mission is to **generate an open-access neuroimaging platform** that provides widely characterized information to advance the design of new treatments for the disease.

The project will feature **data from more than 1,000 healthy participants** aged between 40 and 65 from the Alfa (in Barcelona) and Prevent (in Edinburgh) cohorts.

Since February 2019, data generated as part of the Alfa and TRIBEKA Study are available to the scientific community on the Global Alzheimer's Association Interactive Network (GAAIN) website. This platform allows researchers from around the world to explore broad research cohorts with people with Alzheimer's or at risk of developing the disease.



Supported by:

alzheimer's  association*

2.06

Clinical trials

The BBRC collaborates with the pharmaceutical industry to test drugs that prevent or delay the onset of Alzheimer's disease.

On the December 31, 2019, there was one active clinical trial: AB1601

1

AB1601



The pharmaceutical company **Araclon Biotech, from Grifols**, is the sponsor of this clinical trial that evaluates the efficacy, safety, tolerability and immune response of the drug **ABvac40** in people between 55 and 80 years old with mild amnesic cognitive impairment or in very early stages of Alzheimer's disease.

The study will be conducted with **200 participants** in centers mostly in Spain, but also in France, Italy and Sweden.

2

Clinical trials fails in 2019



Novartis Generation S1 and Generation S2 trials were also conducted in 2019, testing the efficacy of a number of drugs to delay cognitive impairment in people at risk of developing Alzheimer's. However, after analyzing the risk-benefit of the therapy, the sponsor of the study decided to discontinue it.

In addition to these clinical studies conducted at the BBRC, in 2019 the trial of the drug Aducanumab, by Biogen and Eisai, was also suspended due to the impossibility of achieving the planned primary outcomes. According to **Dr. José Luis Molinuevo**, *"it was a promising drug, as in phase IB it had been shown to be able to remove beta amyloid protein plaques deposited in the brain, and it had also achieved a certain impact on cognition. Now, however, we must thank the enormous effort made by the participants, researchers and companies involved in this and other clinical trials of Alzheimer's prevention, as only with the participation of all of them, and driving research, will we achieve any day to find an effective drug to delay or cure the disease"*



2.07

Scientific publications

In 2019, BBRC researchers published 52 articles related to Alzheimer's and other neurodegenerative diseases related to prestigious international scientific journals.



52
Articles

98%

Q1

88%

D1

These are some of the most prominent publications:

Salvadó G, Brugulat-Serrat A, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study. **Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort.** *Alzheimers Res Ther.* 2019 Jan;11(1):12.

Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL. **CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.** *Neuroimage Clin.* 2019 Apr 1;23:101801.

Cacciaglia R, Molinuevo JL, Falcón C, Sánchez-Benavides G, Gramunt N, Brugulat-Serrat A, Esteller M, Morán S, Fauria K, Gispert JD; ALFA study. **APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.** *Neuroimage Clin.* 2019 Apr 8;23:101818.

2.07

Scientific publications



Brugulat-Serrat A, Salvadó G, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study. **Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals.**

Brain Imaging Behav. 2019 Jul;10.1007/s11682-019-00151-2.

Petrone PM, Casamitjana A, Falcon C, Artigues M, Operto G, Cacciaglia R, Molinuevo JL, Vilaplana V, Gispert JD; Alzheimer's Disease Neuroimaging Initiative. **Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI.** *Alzheimers Res Ther.* 2019 Aug 17;11(1):72.

Operto G, Molinuevo JL, Cacciaglia R, Falcon C, Brugulat-Serrat A, Suárez-Calvet M, Grau-Rivera O, Bargalló N, Morán S, Esteller M; ALFA Study, Gispert JD. **Interactive effect of age and APOE-ε4 allele load on white matter myelin content in cognitively normal middle-aged subjects.** *Neuroimage Clin.* 2019 Aug 16;24:101983.

Frisoni GB, Ritchie C, Carrera E, Nilsson P, Ousset PJ, Molinuevo JL, Dubois B, Scheltens P, Minoshima S. **Re-aligning scientific and lay narratives of Alzheimer's disease.** *Lancet Neurol.* 2019 Oct;18(10):918-919.

Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H. **Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.** *Alzheimers Res Ther.* 2019 Nov 28;11(1):94.

Brugulat-Serrat A, Salvadó G, Operto G, Cacciaglia R, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Minguillon C, Fauria K, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study. **White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants.** *Hum Brain Mapp.* 2019 Nov 28.

Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. **Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease.** *Ther Adv Neurol Disord.* 2019 Dec 18;12:1756286419888819.

2.08

Dissemination of results



► Authors of the study of subjective cognitive decline



1

New research on subjective cognitive decline




In January 2019 we announced the results of a new study where we identified that people who perceive an impairment in their cognitive abilities perform worse on cognitive tests and have a lower volume in brain areas affected by Alzheimer's. The results were based on data from Alfa Study participants.

2

New cut-off values for a Biomarker Associated with Alzheimer's



In April 2019 we set a new lower threshold from which the amyloid beta protein, which is linked to Alzheimer's, begins to accumulate pathologically in the brain. The study was conducted with data from the Alfa Study and will allow to detect more candidates for dementia prevention strategies.



3

Analysis of the costs of Alzheimer's



In July 2019, Dr. José Luis Molinuevo participated in an international article that highlighted some of the "hidden" costs of dementia, such as the health consequences of caregivers, the worse quality of life of those affected and their families, and the own costs of the years prior to finding the diagnosis.

2.09

Competitive grants



36%
International

64%
National



Funding from competitive grants and support from national and international institutions allows us to advance research in Alzheimer's prevention.

During 2019 we were awarded a total of 14 grants for projects and human resources

Projects granted



1. Alzheimer's Association Research Fellowship (AARF). *Alzheimer's Association.* Dr. Oriol Grau.

The project studies the relationship between sleep quality and the preclinical phase of Alzheimer's, through the analysis of cognitive performance, magnetic resonance imaging and biomarkers associated with the disease.

2. Alzheimer's Association Research Grant (AARG). *Alzheimer's Association.* Dr. Eider Arenaza-Urquijo.

The aim of the study is to identify modifiable risk factors and brain mechanisms that are related to greater resilience, that is, greater preservation of neuronal integrity in middle age.

3. Alzheimer's Association Research Grant (AARG). *Alzheimer's Association.* Dr. Marta Crous-Bou.

The study aims to investigate whether biological age has any effect on cognitive performance and brain changes associated with the risk of developing Alzheimer's. To determine the biological age, the length of the telomeres will be analyzed, very repetitive DNA sequences located at the end of the chromosomes and which protect them from the loss of information.

2.09



4.

CaixaImpulse. *"La Caixa" Foundation, Caixa Capital Risc and EIT Health.*
Dr. Juan Domingo Gispert

Researchers from the Neuroimaging group of the BBRC have developed an artificial intelligence algorithm that, based on magnetic resonance imaging, facilitates the identification of candidates for studies in the prevention of Alzheimer's disease. The project envisages a proof of concept based on data collected from the Alfa + cohort.

The use of this methodology would reduce selective testing, such as lumbar punctures and positron emission tomography, by 67%, and the costs of recruiting people for prevention studies by up to 50%.

5.

Diagnostics Accelerator: Peripheral Biomarkers Program. *Alzheimer's Drug Discovery Foundation.*

Dr. José Luis Molinuevo.

The goal is to develop a method for detecting beta amyloid, an Alzheimer's-related protein, in blood samples. This system would help identify people in the early stages of Alzheimer's, when there are still no symptoms.

6.

Invigoration Actions
"Research Europe".

Ministry of Science and Innovation - State Research Agency (AEI). Dr. Marc Suárez-Calvet.

7.

Juan de la Cierva Grant for contracts. *Ministry of Science and Innovation - State Research Agency (AEI).* Dr. Natalia Vilor-Tejedor.

8.

Juan de la Cierva Grant for contracts. *Ministry of Science and Innovation - State Research Agency (AEI).* Dr. Marc Suárez-Calvet.



2.09



9.

Juan de la Cierva Grant for contracts. *Ministry of Science and Innovation - State Research Agency (AEI) - Co-financed by the European Social Fund.* Dr. Eider Arenaza-Urquijo.

10.

Health Research Fund - Health Research Projects. *Instituto de Salud Carlos III - Co-financed by the European Social Fund.* Dr. José Luis Molinuevo.

11.

Health Research Fund - Health Research Projects. *Instituto de Salud Carlos III - Co-financed by the European Social Fund.* Dr. Marc Suárez-Calvet.

12.

Health Research Fund - Health Research Projects. *Instituto de Salud Carlos III - Co-financed by the European Social Fund.* Dr. Marta Crous-Bou.

13.

JPND Research. Personalised Medicine for Neurodegenerative Diseases. *EU Joint Programme - Neurodegenerative Diseases Research (Instituto de Salud Carlos III).* Dr. José Luis Molinuevo.

14.

R + D + i Projects “Research Challenges”. *ERDF - Ministry of Science and Innovation - State Research Agency (AEI).* Dr. Juan Domingo Gispert.

2.10

Congresses



Throughout the year, our research staff participated in different conferences.

1

Alzheimer's Association Conference



The BBRC research team almost completely presented the latest advances from the Alfa Study and the Alzheimer's Prevention Program at the **Alzheimer's Association International Conference (AAIC)**.

It is the most important international conference on Alzheimer's research held in Los Angeles from July 14-17.

2

Other outstanding conferences



January 16th-18th

Miami (United States)

Participation of Gemma Salvadó in the Human Amyloid Imaging congress.

March 7th

Florence (Italy)

Participation of Dr. Juan Domingo Gisbert at the XIV SINDEM National Conference.

March 26th-31st

Lisbon (Portugal)

Participation of Dr. José Luis Molinuevo at the International Congress on Alzheimer's and Parkinson's (AD / PD).

► Alzheimer's Association International Conference.



2.10



May 9th

Bonn (Germany)

Participation of Dr. José Luis Molinuevo at the Venusberg Meeting on Neuroinflammation.

May 16th

Malaga (Spain)

Participation of Drs. José Luis Molinuevo and Gonzalo Sánchez-Benavides at the Málaga Alzheimer conference.

May 9th-12th

Rome (Italy)

Participation of Drs. Carles Falcón, Grégory Operto and Raffaele Caccaglia at the annual congress of the Organization for Human Brain Mapping (OHBM).

June 26th

Nice (France)

Participation of Dr. Juan Domingo Gispert at Innovation Alzheimer Summer School.

June 28th

Barcelona (Spain)

Participation of Dr. Gonzalo Sánchez-Benavides at the 74th Conference of the Catalan Society of Neuropsychology.

October 13th and 14th

Vienna (Austria)

Participation of Dr. José Luis Molinuevo at the European Association of Nuclear Medicine (EANM).

October 25th

The Hague (Netherlands)

Participation of Dr. José Luis Molinuevo at the Alzheimer Europe Conference.

November 15 and 16

Munich (Germany)

Participation of Dr. Eider M. Arenaza-Urquijo at the International Conference on Cognitive Reserve in Dementia (RESDEM).

November 22nd

Sevilla (Spain)

Participation of Dr. José Luis Molinuevo at the annual meeting of the Spanish Society of Neurology.

December 4th-7th

San Diego (United States)

Participation of Dr. José Luis Molinuevo at the Clinical Trials on Alzheimer's Disease (CTAD) conference.



trans forma tion.

**We look for solutions and explore
new ways to create relevant results.**

We work to support affected families and to change the social perception of Alzheimer's through social impact, outreach and awareness. With this objective in 2019, we organized therapeutic groups for carers in various cities, and promoted informative content, educational talks and awareness campaigns.

03.

3.01

Therapeutic groups



Since the start of the program in 2012, 747 caregivers have participated in the 77 free therapeutic groups that have been carried out in centers throughout Spain.

In 2019, the therapeutic groups program pushed for the launch of 17 new groups involving 170 caregivers of people with Alzheimer's. The different groups took place in Barcelona, Girona, Alcalá de Henares, Seville, Tenerife and Vigo.

Also, during the year 2019, leisure and cultural outings were organized in the territories where the groups were held, in order to help curb the possible isolation of caregivers and to be able to sustain their social and cultural lives.

The program had the subsidy granted by the Ministry of Health, Social Services and Equality in charge of the tax allocation of personal income tax, with the support of the Department of Labor, Social Affairs and Families of the Generalitat de Catalunya in charge of the allocation of 0.7% of personal income tax and funding by the Diputació de Girona, Barcelona City Council and Agbar.

17

Therapeutic groups



Interventions group to caregivers



Support group for people with Alzheimer's in Galicia, Tenerife, Madrid, Andalusia (through IRPF)

3.01

The mission of therapeutic groups is to offer information and resources to facilitate understanding and acceptance of the disease by the caregivers.

Throughout the sessions, they discover tools to live and coexist with people living with dementia and reduce the impact derived from their role as caregivers, thus improving their quality of life.

In 2019, the second edition of the online course **“Conducting therapeutic groups and advising family carers of people with Alzheimer’s disease”** was held, a university extension program for therapists carried out in conjunction with the “la Caixa” Foundation and the Institute of Continuing Education of the University of Barcelona. The course consists of 75 hours of online self-training and 8 hours of face-to-face training in Málaga, Las Palmas and Tenerife.



 “la Caixa” Foundation

 **Generalitat de Catalunya**

 **Agbar**
Fundació

 **Diputació de Girona**

 **Ajuntament de Barcelona**

 **GOBIERNO DE ESPAÑA**
 **MINISTERIO SANIDAD, SERVICIOS SOCIALES E IGUALDAD**

Supported by:

 **Generalitat de Catalunya**
Departament de Treball,
Afers Socials i Famílies

3.02

Dissemination activities

1

New campaign: When you take care of yourself, Alzheimer's takes a step back



The Pasqual Maragall Foundation promoted the awareness campaign **"When you take care of yourself, Alzheimer's takes a step back"** which visited Bilbao and Madrid. More than **1,300 people** approached a set of tents set up in both cities where they were able to take part in a circuit of activities with tips to prevent Alzheimer's.

Thanks to research, today we know that 1 in 3 cases of dementia could be prevented with the adoption of

healthy living habits and therefore, with different activities children and grown-ups were able to playfully learn some of the keys to the five axes of active aging: socialization, cognitive activity, physical activity, nutrition and cardiovascular health and sleep. The campaign featured the collaboration of well-known faces such as publicist Risto Mejide and actor Peter Vives.

2

Blog "Let's talk about Alzheimer"



The Pasqual Maragall Foundation offers quality, rigorous, accurate and up-to-date information on Alzheimer's in the blog "Let's talk about Alzheimer's". In this way, it aims to answer questions about the disease to people affected, relatives, caregivers and



► Presentation of the campaign in Bilbao.

3.02




642,123

Blog visits

<https://blog.fpmaragall.org/>

those interested in Alzheimer's. Thanks to the quality of its contents the blog received this year the **Accredited Medical Web certification, granted by the Barcelona Medical Association.**

During 2019 an effort was made to increase the number of publications and improve the published content. 58 new articles and 3 new guides were published with additional information on the disease, reaching a total of 149 articles and 8 guides. During the year, more than **642,123 blog visits and 815,343 page views** were recorded.



3

Project “Life Soundtrack”




In 2019, the Pasqual Maragall Foundation worked on the design of the new edition of the “Life Soundtrack” project, this time within the framework of Community Services for 4th ESO students (15-16 years old).

It is attended by **30 students** from two colleges who, after a period of training, carry out sessions for the production and listening of personalized soundtracks for the elderly with cognitive impairment.

The aim is to work on knowledge and awareness of Alzheimer's disease and intergenerationality.

Supported by:

 “la Caixa” Foundation

3.02

2,400
Visitors

4

Second edition of the Brain Film Fest



From 15 to 17 March, the Center for Contemporary Culture of Barcelona (CCCB) hosted the **second edition of the Brain Film Fest**, of which the Pasqual Maragall Foundation is the driving force and co-organizer.

This is an international film festival dedicated to show and promote the creation and dissemination of short films about any aspect of the brain, its incredible abilities or even its pathologies.

More than 200 films from around the world took part in the competition for the IX Solé Tura Prize, which was finally awarded to the film Carlotta's Face.

The initiative brought together **2,400 people** who were able to enjoy a whole program of activities related to the brain: talks, round tables, a magic show, a film controlled by the mind, the opening and closing films, documentaries out of competition and, of course, the screening of the twenty-two short films selected for the final competition.

In addition, the Brain Film Fest premiered in Madrid on March 19, with a series of screenings and presentations at the Telefónica Foundation.

5

“Sign for a future without Alzheimer’s” signature campaign



During 2019, the Pasqual Maragall Foundation continued to promote the signature campaign that aims to involve the population and raise awareness among the competent bodies about the need to have more resources for Alzheimer’s research.

In 2019, more than **220,000 people** joined the initiative, reaching a total of more than **300,000 signatures** since the start of the campaign.



3.02



82,000

**Conversations
in the street**

6

Awareness on the street



The Pasqual Maragall Foundation has teams of informants on the streets of various cities throughout Spain.

During 2019, they talked to more than **82,000 people** about Alzheimer's and its impact and explained the Foundation's projects to drive research into the disease.

7

Campaign #Alzheimer28A



The Pasqual Maragall Foundation and the Spanish Alzheimer's Confederation (CEAFA) launched the **#Alzheimer28A** campaign as part of the April 28 general election. Associations, organizations, researchers and citizens joined the action on social media to ask political parties for a public commitment for the fight against Alzheimer's.

8

Open days



During 2019, the Pasqual Maragall Foundation and the Barcelonaβeta Brain Research Center opened their doors to the public on two occasions: on 15th of June and 26th of October.

In June, Dr. Marc Suárez-Calvet presented his BioAlfá project to about fifty partners and collaborators and, together with part of the Foundation's team, guided the guests through the facilities where the scientific research



3.02



is carried out. In October, as part of the 48h Open House architecture festival, more than 150 people were able to get to know the Foundation's and BBRC facilities as well as the Foundation's scientific research and social intervention work.

9

We dismantle myths during Brain Week



On the occasion of this global awareness campaign held from March 11th to 17th, we collected in our blog 10 widespread myths about Alzheimer's in order to clarify what is true and what is false.

Thus, with the scientific rigor of our experts, we contributed to improve knowledge of the disease. We also gave several dissemination talks at secondary schools in Barcelona, as part of an initiative organized by the City Council.

10

The IV Annual Meeting gives voice to the protagonists of the fight against Alzheimer's



Under the title "**Let's give voice to Alzheimer's research**", the Pasqual Maragall Foundation held an event to give visibility to the essential role of all people who join forces in the fight for a future without Alzheimer's. The event, held at the Forum Auditorium on June 27th, was attended by nearly **1,000 people**.

Journalist Ana Boadas was in charge of leading the event, which was witnessed by partners, collaborators, participants in scientific studies and caregivers, as well as a presentation by Dr. José Luis Molinuevo on the importance of biomarkers for the early detection and prevention of Alzheimer's.

1,000
People

3.02

11

Talks, seminars and conferences



February 12th.

Talk on memory at the Teatre Lliure by Dr. Nina Gramunt, in the context of the Brain Film Fest.

February 14th.

Lecture on retrogenesis in Alzheimer's by Dr. Nina Gramunt at the CCCB, as part of the Brain Film Fest.

February 16th.

Masterclass by Glòria Oliver at the Museo de Evolución Humana in Burgos, as part of the STEM Talent Girl program.

February 19th.

Talk on neuroscience and magic by Dr. Jordi Camí at the Espai Brossa in Barcelona.

February 27th.

Talk by Dr. Nina Gramunt on research into Alzheimer's disease at Mútua Granollers.

March 11th-15th.

Informative talks at secondary schools by Dr. Nina Gramunt, as part of Brain Week.

March 14th.

Glòria Oliver's participation in a round table to attract female talent to the II Hyundai Forum.

March 20th.

Talk by Dr. Sandra Poudevida at the El Garrofer School in Viladecans.

March 26th.

Talk "Prevention and quality of life. Together adding efforts to overcome Alzheimer's" by Glòria Mas and Desirée Piromalli at the Barcelona College of Censors.

April 10th.

Live broadcast via Facebook by the Foundation with the participation of Dr. Nina Gramunt with the aim of resolving doubts about Alzheimer's.

May 13th.

Talk "Prevention and quality of life. Together adding efforts to overcome Alzheimer's" by Glòria Mas at the Salus Infirmorum Clinic in Banyoles.

May 21st.

Informative talk on pollution and Alzheimer's in Blanes by Dr. Marta Crous-Bou, as part of Pint of Science.

May 23rd.

Talk for caregivers in Accent Social de Cerdanyola del Vallès by Glòria Mas.



3.02



May 25th.

Informative conference of Dr. Grégory Operto on neuroimaging in Menton (France).

June 18th.

Informative talk on pollution and Alzheimer's at the Calella Research and Innovation Conference by Dr. Marta Crous-Bou.

July 6th.

Informative talk at the Municipal Library of Bilbao by Dr. Nina Gramunt as part of the campaign "When you take care of yourself, Alzheimer's takes a step back".

July 9th.

Event: "The voices of the Pasqual Maragall Foundation in Girona"

July 10th.

Participation of Dr. Jordi Camí in the debate on neurodegenerative diseases of the Health Consortium of Catalonia.

July 17th.

Informative talk on Alzheimer's at the Reig Jofré Laboratories by Dr. Nina Gramunt.

September 18th.

Informative talk at the American International Institute in Madrid by Dr. Nina Gramunt as part of the campaign "When you take care of yourself, Alzheimer's takes a step back".

September 27th.

Participation of Dr. Marc Suárez-Calvet at the European Research Night with an informative talk on his BioAlfa project.

October 22nd.

Participation of Dr. Karine Fauria at the AQUAS gender conference.

October 28th and November 11th.

Participation of Dr. Jordi Camí in a series of talks on the memory of the Club Roma at the Palau Macaya in Barcelona.

November 9th.

Participation of Dr. José Luis Molinuevo at the BCNSpiracy Talks conference as part of Science Week.

November 16th.

Informative talk on Alzheimer's prevention and presentation of the therapeutic groups at the Bancaja Cultural Center (Valencia) by Drs. Nina Gramunt and Sandra Poudevida.

November 18th.

Talk on the care of caregivers of Alzheimer's patients in Cerdanyola del Vallès, given by Glòria Mas.

November 26th.

Participation of Glòria Oliver in the conference "Reality and Challenges of private funding in research and health organizations" of the Spanish Fundraising Association.

26 de noviembre.

Training by Dr. Nina Gramunt on prison officials on cognitive aging in Madrid.

December 3rd.

Talk "Alzheimer's and its psychological repercussions on the caregiver. How to intervene" in the University Classroom of Castellar del Vallès.

December 12th.

Talk on Alzheimer's prevention at the Jaume Fuster Library in Barcelona, given by Dr. Nina Gramunt.

3.02

12

Social media in 2019



Facebook



Twitter



LinkedIn



Youtube

48,303

Followers

6,908

Followers

3,027

Followers

771

Subscribers

21,834

Reactions

5,254

Retweets

1,971

Recommendations

110.965

Views

1,400

Comments

10,842

Likes

63

Comments

9,137

Shares

3,346

Mentions

274

Shares

3.02

13

Awards and distinctions



National Prize for Scientific Patronage

The Generalitat de Catalunya and the Catalan Foundation for Research and Innovation (FCRI) awarded the Pasqual Maragall Foundation the National Scientific Patronage Award 2018, for its intense work to promote Alzheimer's research. The award ceremony was held in December 2019 at the Teatre Nacional de Catalunya.

► Dr Jordi Camí and Diana Garrigosa receiving the National Prize for Scientific Patronage



Procura Awards

As part of the 7th edition of the Procura Awards, the Illustrious College of Solicitors of the Courts of Barcelona awarded the Solidarity Award to the Pasqual Maragall Foundation in recognition of its social work and the research on Alzheimer's that leads to term.

"The cause of the month" of migranodearena.org

In March 2019, the Pasqual Maragall Foundation won the "cause of the month" award from the migranodearena.org solidarity crowdfunding platform for being the organization with the most donations of the month, with a total of 199.

"Assets of the Agreement" badge

The therapeutic groups of the Pasqual Maragall Foundation were recognized with the "Assets of the Agreement" badge of the Citizen Agreement for an Inclusive Barcelona program, which works to achieve a more inclusive Barcelona with a higher quality of life for everyone.



con nec tion.

We work in network and with a global vision, cooperation will take us further.

During 2019, the social base of the Pasqual Maragal Foundation did not stop growing and closed the year with more than 33,000 members who are the essential basis to advance the project. In addition, there was the support of companies and collaborators who promoted more than 200 solidarity initiatives to continue research into Alzheimer's prevention.

04.

4.01

Network of partners and donors



The Claß membership network currently consists of 78 members who contribute annually of € 135,483.


On June 12th, Claß members were able to see first-hand the facilities of the Foundation and the BBRC and the Alzheimer's prevention projects that are being carried there.



In 2019, we welcomed **9,149 new members**, who joined our project and contributed of **€ 888,494**. In addition, a voluntary quota increase campaign was launched, which was well received. All this allowed us to close the year with **33,657 members** who represented a total contribution of **€ 4,256,938**.

In terms of donations, **2,315** were received, representing a total income of **€ 200,946**, of which more than **€ 63,000** was obtained thanks to the contributions within the framework of the global solidarity movement: Giving Tuesday.

9.149
New members



4.02

Actions and solidarity entities



SMS at the 28058

Thanks to the collaboration of Movistar, Vodafone, Orange and Euskaltel, through our SMS numbers 28058 (€ 1.20) and 38058 (€ 6), in 2019 an income of € 4,364 was received.

2019 was full of actions, events and solidarity activities promoted by individuals and organizations that raised funds for the Pasqual Maragall Foundation.

Highlights include the organization of **205 solidarity initiatives** that raised **€ 491,448**, and the donation of **€ 15,750** from the communication agency Atrivia, among others.

1

Closing of the campaign "Cèntim a cèntim, fem memòria"



The initiative, the result of a collaboration agreement between the Catalan start-up Worldcoo and the Vienna establishments, was launched in November 2018 to raise funds for research for Alzheimer's disease.

For almost 4 months, **622,000 micro-donations** were obtained thanks to the rounding of the amount of all orders paid by card and which represented a collection of more than **€ 238,000**.

2

Closing of the "Healing smiles" campaign



On March 15th, the Granollers Mutual Society held the Mutual Society Day Gala at the Granollers Auditorium Theater, where it announced a record collection of **€ 27,772** at the close of the fourth edition of the "**Healing Smiles**" campaign.

On this occasion, they organized a handball match, sale of bracelets, Christmas lottery, among other activities, to raise funds for Alzheimer's disease research at the Pasqual Maragall Foundation.



4.02



3

Solidarity concert by Andrea Motis and Joan Chamorro



On January 12th, the AXA Auditorium in Barcelona hosted the solidarity concert of the quartet led by Andrea Motis and Joan Chamorro.

The initiative was born from the retired transporter Josep Maria Pérez, who has collaborated with multiple solidarity projects for the Pasqual Maragall Foundation. The event brought together about 600 people, full capacity, who left more than **€ 13,000** for Alzheimer's research.

4

New solidarity paella from the Port of Barcelona



During the sixth edition of this lunch organized by Josep Maria Pérez, more than 530 people and 27 private sponsors raised **€ 20,000** for research projects of the Pasqual Maragall Foundation.

5

3rd Solidarity Xmas Tree edition



Organized by the entity Together +, the initiative managed to raise **€ 138,000** for the projects of the Pasqual Maragall Foundation and the Pequeño Deseo Foundation.

The collection was the result of the auction of 14 Christmas trees created by the luxury brands Alfons & Damián, Brunello Cucinelli, Cartier, Castañer, Chopard, Hermes, La Perla, Lladró, Loewe, Luzio, Natura Bissé, Rabat, Santa Eulalia, ZE Garcia.

The auction, which closed with a solidarity dinner on December 3rd, took place during a charity gala held at the Hotel Majestic in Barcelona.

4.02

Other outstanding initiatives were the VIII Somos Uno Solidarity Day at RCDE Stadium, the Señor Gañán Concert at the Teatro Lope de Vega in Ocaña (Toledo), the solidarity café of Il Caffè di Francesco, the solidarity lithographs of Serveis Mèdics Penedès, the initiative “Kms. To remember” by DOMUS VI, among others.

6

Gala dinner “We will remember for those who can not”



On March 22nd, the Rotary Club Barcelona Pedralbes organized a Gala dinner at the Centenary Hall of the Royal Polo Club of Barcelona.

The event brought together more than 100 people, including various figures from the worlds of politics and business, and raised more than **€ 13,000** for Alzheimer’s research.



7

Solidarity and therapeutic concert in Santa Maria del Mar



On May 11th, the Andreuenca Musical Association promoted a solidarity concert with the support of the Association of Relatives of Alzheimer’s Patients of Barcelona (AFAB) and the Pasqual Maragall Foundation.

The Jove Banda Simfònica de Barcelona gave an exciting recital in the emblematic basilica of Santa Maria del Mar, aimed especially at people with Alzheimer’s, carers and relatives of those affected. The event was attended by more than 700 people.



© Jordi Sueiro

4.03

Solidarity
celebrations

1

One hundred newlyweds opt for a memorial against oblivion in 2019



The Foundation offers couples the opportunity to give away personalized postcards in exchange for a donation for research into Alzheimer's prevention. In 2019, **€ 29,030** was raised.

2

Solidarity of the Pablo López Fan Club



Every year for the singer's birthday, Pablo López's fans present him with micro-donations for the benefit of charitable organizations through the **migranodearena.org** platform.

On this occasion, more than 700 donors managed to raise **€ 12,218** for the fight against Alzheimer's from the Pasqual Maragall Foundation.



4.04

Challenges and solidarity sports



1

A marathon for a father's day



In March, the athlete Laura Arín ran the Barcelona Marathon with a solidarity cause. Under the motto "I will remember your dreams for you", she ran 42.195 km in honor of his father, who suffers from Alzheimer's, and all those affected by the disease. Through the migranodearena.org platform, she managed to raise **€ 1,543** for research into Alzheimer's prevention.



2

Sosciathlon for a future without Alzheimer



On September 29th, the fifth edition of the Sosciathlon was held in Salou. A day full of sports activities that managed to raise **€ 22,000**.

The beneficiaries of this solidarity activity were the Hospital Sant Joan de Déu and the Pasqual Maragall Foundation, with **€ 11,000** each.



4.05

Solidarity schools



- The **Germans Corbella school in Cardedeu** held a Christmas solidarity fair where they raised **€ 2,723** for the Pasqual Maragall Foundation.
- The **Ermengol IV Institute in Bellcaire d'Urgell** organized a solidarity breakfast in favor of the Pasqual Maragall Foundation.
- The fifth-graders from the **El Garrofer School in Viladecans** set up a stall at the Fira de Sant Isidre in their town where they sold products and handicrafts with the aim of raising money for the Pasqual Maragall Foundation.

trust.

**We build long-term projects
and relationships based on trust.**

We have a transparency policy, and a transparency
and accountability code.

05.



5.01

About us



Transparency and good practices:

The Pasqual Maragall Foundation and the Barcelonaβeta Brain Research Center have a policy and a code of good practice in transparency and accountability, and adhere to the code of good scientific practice of the Barcelona Biomedical Research Park (PRBB).

1

The Pasqual Maragall Foundation



With the vision of achieving **a future without Alzheimer's**, the Pasqual Maragall Foundation promotes and develops excellence in biomedical research to help provide decisive solutions to this disease.

The aim is to **prevent its occurrence**, determining what factors affect its onset and development and designing interventions to act before it is too late.

The Foundation works both to raise social awareness about the effects of Alzheimer's and to contribute to the acceptance and normalization of the disease. It also aims to **convey to society the importance of scientific research to find solutions**.

Until these solutions arrive, the Foundation is also committed to **improving the quality of life of those affected and their caregivers**.

2

The Barcelonaβeta Brain Research Center



The Barcelonaβeta Brain Research Center (BBRC) is a research center dedicated to the prevention of Alzheimer's disease. It was created in 2012 by the Pasqual Maragall Foundation, with the support of the Pompeu Fabra University.

The mission of the BBRC is to provide innovative solutions to decipher and prevent biological changes and cognitive dysfunction associated with neurodegenerative diseases.

Its researchers carry out **research projects of neuroimaging and primary and secondary Alzheimer prevention**, and actively participate in studies and international work groups focused on the prevention of the disease.

5.02

Origin and destination of resources



At the Pasqual Maragall Foundation we work to achieve a future without Alzheimer's through biomedical research for the prevention of this disease.

To achieve this, we invest most of the resources obtained in research programs and communication and dissemination actions to increase social support for our cause.

We also allocate a portion of the resources to raise new funds to ensure the long-term sustainability of ongoing scientific programs.

Budget

▲ **€ 10,961,050**

Pasqual Maragall Foundation

▲ **€ 6,005,549**

BBRC Research Center

▲ **€ 4,955,501**



5.02



Total revenues € 10,961,050


Current income € 10,787,272

● Patrons, partners and donors (53%)	€ 5,712,600
● Social area and dissemination (1%)	€ 145,940
● Research project (41%)	€ 4,456,466
● Clinical trials (5%)	€ 472,266

Adjustments for capital subsidies* € 119,646

Financial income* € 54,131

*Not included in the graphic




Total expenditures 10,931,420 €

Current expenses € 10,861,774

● Research program (66%)	€ 7,189,771
● Communication and sensitivity (11%)	€ 1,202,543
● Social area and dissemination (3%)	€ 295,838
● Investment in network recruitment of partners and donors (17%)	€ 1,858,915
● Administration (3%)	€ 314,707

Financial income* € 69,646

*Not included in the graphic



5.03

Collaborators



Our most sincere thanks to the network of partners and donors and to the entities, companies and professionals who have supported our research through their contributions and collaborations.

Our gratitude also to all the volunteers who dedicate their time and help us in the organization of actions and events.

Fundación Adey and Seguros Santa Lucía were two of the companies that most collaborated with our cause.

See the complete list of collaborators at:

fpmaragall.org/memoria2019

Sponsorship Board

In 2019 we highlight the increase in the contributions of Fundación Renta Corporación.

Our thanks to all the entities and companies of our Sponsorship Board for your support and your trust.

Strategic Partners



Special Partners



Partners



Associated companies



Academic and scientific partners



With the support of:




5.04

Academic collaborators



- EPAD consortium
- AMYPAD consortium
- Barcelona Supercomputing Center
- Pompeu Fabra University
- Polytechnic University of Catalonia
- Universitat Autònoma de Barcelona
- ISGlobal
- Genomic Regulation Center
- National Center for Cardiovascular Research
- Hospital del Mar Institute for Medical Research
- August Pi i Sunyer Biomedical Research Institute
- Hospital Clínic de Barcelona
- University of Gothenburg
- Amsterdam VU University Medical Center
- University College of London (UCL)

► Barcelona Supercomputing Center



5.05

**pasqual
maragall
foundation**



**Configuration
from February,
2020**

Board

Founder and Honorary President

Pasqual Maragall

Founder

Diana Garrigosa

President

Cristina Maragall

1st Vice President

Santiago de Torres

2nd Vice President

Montserrat Vendrell

3rd Vice President

Jordi Camí

Chairpersons

Núria Basi

Joaquim Boixareu

Joaquim Coello

Marta Grabulosa

Airy Maragall

Guillem Maragall

Jordi Mercader

Arcadi Navarro

Marcel Prunera

Narcís Serra

David Vegara

**Antoni Vila / Àngel Font "la Caixa"
Foundation**

**Chairpersons representing
the Sponsorship Board**

Antonio García

Vice President ACS Foundation

Miquel Molins

Banco Sabadell Foundation

Secretary

Ignasi Costas - RCD

Vice secretary

Alberto Ouro - RCD

Executive Commission

President

Montserrat Vendrell

Chairpersons

Jordi Camí

Joaquim Coello

Marcel Prunera

Arcadi Navarro

Antoni Vila "la Caixa" Foundation

Àngel Font "la Caixa" Foundation

Secretary

Ignasi Costas - RCD

Vice secretary

Alberto Ouro - RCD

5.05

barcelonaβeta
BRAIN RESEARCH CENTER



**Configuration
from February,
2020**

Board

President

Montserrat Vendrell

Director

Arcadi Navarro

Chairpersons

Arcadi Navarro

Jaume Badia

Jordi Camí

Joaquim Coello

Josep Martorell

Francesc Posas

Marcel Prunera

Antoni Vila "la Caixa" Foundation

Secretary

Ignasi Costas

Vice secretary

Alberto Ouro

Executive Commission

President

Montserrat Vendrell

Chairpersons

Jordi Camí

Joaquim Coello

Marcel Prunera

Antoni Vila "la Caixa" Foundation

Arcadi Navarro

20
19

**A year
of intense
activity**

20 19

**Annual
report**

**"Nowhere is it written
that Alzheimer's is invincible"**

Pasqual Maragall
October, 2007

Wellington, 30
08005 Barcelona
933 160 990
info@fpmaragall.org
info@barcelonabeta.org

www.fpmaragall.org
www.barcelonabeta.org

**pasqual
maragall
foundation**

barcelonaβeta
BRAIN RESEARCH CENTER